While there is no standard of care for PBL , current recommendations include dose-adjusted EPOCH ( etoposide , vincristine , doxorubicin , cyclophosphamide , and prednisone ) , with or without bortezomib .
A Rare Presentation of HIV-Negative Plasmablastic Lymphoma: A Diagnostic Dilemma. Plasmablastic lymphoma (PBL) and plasmablastic plasma cell myeloma (PCM) have many overlapping characteristics. Clinical correlation can help make the distinction between the two entities. Human immunodeficiency virus- (HIV-) negative PBL is a rare disease, making the diagnosis more challenging. While there is no standard of care for PBL , current recommendations include dose-adjusted EPOCH ( etoposide , vincristine , doxorubicin , cyclophosphamide , and prednisone ) , with or without bortezomib . We report an aggressive case of HIV-negative plasmablastic lymphoma and discuss the challenge in establishing a diagnosis. We review the literature regarding this disease and current recommendations for treatment.
### Instruction:
            Given the context about compound efficacy for the given treatment mentioned within the input, mentioned the compounds 
            that can co-occur for the mentioned treatment

            ### Input:
            A Rare Presentation of HIV-Negative Plasmablastic Lymphoma: A Diagnostic Dilemma. Plasmablastic lymphoma (PBL) and plasmablastic plasma cell myeloma (PCM) have many overlapping characteristics. Clinical correlation can help make the distinction between the two entities. Human immunodeficiency virus- (HIV-) negative PBL is a rare disease, making the diagnosis more challenging. While there is no standard of care for PBL , current recommendations include dose-adjusted EPOCH ( etoposide , vincristine , doxorubicin , cyclophosphamide , and prednisone ) , with or without bortezomib . We report an aggressive case of HIV-negative plasmablastic lymphoma and discuss the challenge in establishing a diagnosis. We review the literature regarding this disease and current recommendations for treatment.

            ### Response:
            etoposide, vincristine, doxorubicin, cyclophosphamide, prednisone, bortezomib
            